世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

遺伝子発現解析市場:製品別(消耗品、機器)、用途別(創薬、診断)、エンドユーザー別(製薬・バイオテクノロジー企業、学術・研究機関、その他)、地域別、2030年までの世界予測


Gene Expression Analysis Market based on by Products (Consumable, Instruments), by Application (Drug Discovery, Diagnostics), by End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others), Regional Outlook Global Forecast up to 2030

最近10年間は、シーケンシングの高コストが市場拡大の大きな障壁となっていた。ヒトゲノム・プロジェクトは2003年、最初のヒトゲノムの配列を決定するために27億米ドルの資金を必要とした。しかし、シーケンスの... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IHR Insights
アイエイチアールインサイト
2024年1月3日 US$4,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
230 英語

 

サマリー

最近10年間は、シーケンシングの高コストが市場拡大の大きな障壁となっていた。ヒトゲノム・プロジェクトは2003年、最初のヒトゲノムの配列を決定するために27億米ドルの資金を必要とした。しかし、シーケンスのスピード向上とコスト削減を目標に、ゲノミクス分野の技術的進歩は著しい。
長年にわたり、NHGRI(国立ヒトゲノム研究所、米国)は、多くのスポンサー付きゲノム配列決定センターにおける配列決定価格を追跡し、ヒトゲノム計画後の数年間のゲノム配列決定のコストを計算してきた。このデータに基づき、NHGRIは、2006年には完成したヒトゲノムシーケンスの生成には2000万~2500万米ドル以上かかったと推定しているが、2015年後半には、高品質のヒト全ゲノムシーケンスドラフトの生成コストは1500米ドルを下回り、全エクソームシーケンスの生成コストは一般的に1000米ドルを下回っている。
遺伝子発現分野の大手企業は、絶えず新しく改良された技術を市場に投入している。これにより、業界はより経済的な検査サービスの導入を見ることができる。2017年1月、イルミナ(米国)はNovaSeqシリーズを発表し、今後数年間でゲノム/トランスクリプトームのシーケンスコストが100米ドル程度まで低下すると予測されている。
シーケンスの低コスト化は、ヘルスケア企業にとって新たな展望を開く可能性が高い。例えば、シーケンシングの低コスト化により、研究者は数千人のゲノムのシーケンスを行うことができるようになり、その結果、疾患の病因を決定するためのより良いデータセットが得られることになる。さらに、コストが下がれば、珍しい疾患を持つ人の評価や治療がより迅速に行えるようになる。その結果、シーケンスコストの大幅な低下が遺伝子発現解析市場の成長を促進する主要な原動力となる可能性が高い。
調査方法
二次調査で世界の遺伝子発現解析市場のシナリオを基本的に理解した後、広範な一次調査を実施した。遺伝子発現解析市場を提供するティア1およびティア2企業の主要メーカー、ディストリビューター、チャネルパートナーのCレベルおよびDレベルのエグゼクティブ、プロダクトマネージャー、マーケティングおよびセールスマネージャー、ならびに学術機関、研究機関、CROの担当者など、供給側と需要側の業界専門家に多数の一次インタビューを実施した。これらのインタビューは5つの主要地域で行われた:北米、欧州、アジア太平洋、その他の地域(中南米、中東、アフリカ)の5つの主要地域で実施した。一次インタビューのうち、供給側と需要側の参加者は、それぞれ約70%と30%に参加した。アンケート、Eメール、オンライン調査、直接面談、電話インタビューなどを用いて、この主要データを収集した。主な参加者のシェアは以下の通りである:

本調査のセグメンテーション範囲は以下の通り。
エンドユーザーに基づく遺伝子発現解析市場
- 製薬・バイオテクノロジー企業
- 学術・研究機関
- その他
製品別:遺伝子発現解析市場
- 消耗品
- 機器
タイプ
 ポリメラーゼ連鎖反応
 次世代シーケンス
 DNA マイクロアレイ
 その他
用途別の遺伝子発現解析市場
- 創薬
- 診断
遺伝子発現解析市場:地域別
- 北米
米国
カナダ
- ヨーロッパ
ドイツ
o イギリス
o フランス
o イタリア
o スペイン
o 残りのヨーロッパ(RoE)
- アジア太平洋(APAC)
o 中国
o 日本
o インド
o オーストラリア
o 韓国
o その他のアジア太平洋地域(RoAPAC)
- ラテンアメリカ(LATAM)
o ブラジル
o アルゼンチン
o その他の南米地域
- 中東・アフリカ(MEA)
o アラブ首長国連邦
o トルコ
o サウジアラビア
o 南アフリカ
o その他の中東・アフリカ
遺伝子発現市場は、製品、アプリケーション、エンドユーザー、地域セグメントに分けられる。市場は消耗品と機器の2つのカテゴリーに分けられる。ポリメラーゼ連鎖反応、次世代シーケンシング、DNAマイクロアレイ、その他のツールはさらに細分化される。用途別には、創薬と診断に分けられる。製薬・バイオテクノロジー企業、学術・研究機関、その他がエンドユーザーである。北米、欧州、アジア太平洋、ラテンアメリカで調査されている。
次世代シーケンシング(NGS)は、病気に関連する遺伝的変化を分析するためにDNAまたはRNAの塩基配列を決定する技術である。何百万ものDNA配列を同時に決定できることから、超並列シーケンサーとも呼ばれる。
次世代シーケンサーは、臨床診断におけるNGS技術の応用の増加、シーケンシングプロセスのスピード、手頃な価格、正確さなどの理由により、予測期間を通じて大幅に増加すると予測される。さらに、わずかなサンプル投入で正確な結果が得られるサンガーシーケンスアプローチに対するNGSの利点が、市場の拡大を後押ししている。
バイオマーカー同定、がん研究、個別化医療などの用途で次世代シーケンス技術の利用が拡大していることが、市場拡大の原動力となっている。例えば、次世代シーケンシング技術の急速な登場は、遺伝子ごとのアプローチから、症候ベースのパネルシーケンス、診断用エクソームシーケンス(DES)、診断用ゲノムシーケンス(DGS)に基づく精密モデルへとシフトし、ゲノミクスと医療診断に革命をもたらしました。疾病管理予防センターによると、各国が大規模集団の分析に率先して取り組む中、2025年までに世界で6,000万人以上がゲノムの塩基配列決定を受けることになる。さらに、無細胞血漿次世代シーケンサー(cfNGS)は、病原体DNAを検出することにより、血液中のウイルス、細菌、真菌感染を診断するために使用される。
さらに、病気の根本的な原因を突き止めるために次世代シーケンシング技術を採用するために、大学、学術研究機関、研究機関がいくつかのイニシアチブを開始したことが、このセグメントの成長を押し上げると予想される。例えば、Rocheは次世代シーケンシング(NGS)技術を向上させるため、2021年12月にAVENIO Edge Systemを導入する予定である。一方、Cerba Researchは2021年1月に、COVID-19を含む感染症に対するワクチン開発のための研究を増やすために、PCRベースと次世代シーケンシングベースの2つのCOVID-19探索ツールを導入した。次世代シークエンシングベースのアッセイは、SARS-CoV-2を含む呼吸器系ウイルスの全ゲノムシークエンシングを大幅に簡素化した。このような進歩は、次世代シーケンサーをイノベーションの基盤として利用している臨床研究や組織に大きな後押しを与える。
主要企業は、市場での存在感を高めるために、パートナーシップ、契約、提携、新製品の発表、地理的拡大、合併、買収など、さまざまな成長戦略を採用している。市場参入企業には、QIAGEN、Quest Diagnostics Incorporated、F. Hoffmann-La Roche Ltd、Illumina, Inc、Novogene Corporation、PerkinElmer Inc、Bio-Rad Laboratories、Thermo Fisher Scientific, Inc、Agilent Technologies、Promega Corporation、Luminex Corporationなどがある。地域やサービスポートフォリオの拡大、M&Aは、これらのプレーヤーが採用する主要な戦略的事業である。
- 本レポートは、遺伝子発現解析市場の最も重要な属性を示しており、これが市場を牽引し、機会を提供しています。
- この調査レポートは、遺伝子発現解析市場の成長を市場のいくつかのセグメントに基づいて詳細に分析します。
- 遺伝子発現解析市場の過去と現在の動向予測を提示します。
- また、遺伝子発現解析市場の主要企業の主要戦略や能力などの競争分析も提示しています。

ページTOPに戻る


目次

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. End User: Market Size & Analysis
5.1. Overview
5.2. Pharmaceutical and Biotechnology Companies
5.3. Academic and Research Institutes
5.4. Others
6. Product: Market Size & Analysis
6.1. Overview
6.2. Consumable
6.3. Instruments
7. Application: Market Size & Analysis
7.1. Overview
7.2. Drug Discovery
7.3. Diagnostics
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. QIAGEN
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F. Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. PerkinElmer Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Bio-Rad Laboratories, Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Promega Corporation
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. PACBIO
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Illumina Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Agilent Technologies Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Thermo Fisher Scientific Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Oxford Nanopore Technologies
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy

11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

ページTOPに戻る



図表リスト

Tables
TABLE 1. GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 2. GENE EXPRESSION ANALYSIS MARKET VALUE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. GENE EXPRESSION ANALYSIS MARKET VALUE FOR ACADEMIC AND RESEARCH INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. GENE EXPRESSION ANALYSIS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 6. GENE EXPRESSION ANALYSIS MARKET VALUE FOR CONSUMABLE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. GENE EXPRESSION ANALYSIS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 9. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DRUG DISCOVERY , BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 16. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 17. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 19. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 20. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 21. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 22. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 23. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 25. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 26. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 29. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 30. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 32. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 35. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 38. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 39. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 40. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 41. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 44. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 45. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 46. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 47. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 48. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 51. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 54. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 55. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 57. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 60. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 61. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 62. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 63. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 64. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 65. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 66. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 67. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 68. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 69. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 70. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 71. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 72. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 73. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 74. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 75. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 76. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 77. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 78. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 79. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 80. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 81. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 82. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 83. QIAGEN : FINANCIALS
TABLE 84. QIAGEN : PRODUCTS & SERVICES
TABLE 85. QIAGEN : RECENT DEVELOPMENTS
TABLE 86. F. HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 87. F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 88. F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 89. PERKINELMER INC.: FINANCIALS
TABLE 90. PERKINELMER INC.: PRODUCTS & SERVICES
TABLE 91. PERKINELMER INC.: RECENT DEVELOPMENTS
TABLE 92. BIO-RAD LABORATORIES, INC.: FINANCIALS
TABLE 93. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 94. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 95. PROMEGA CORPORATION: FINANCIALS
TABLE 96. PROMEGA CORPORATION: PRODUCTS & SERVICES
TABLE 97. PROMEGA CORPORATION: RECENT DEVELOPMENTS
TABLE 98. PACBIO: FINANCIALS
TABLE 99. PACBIO: PRODUCTS & SERVICES
TABLE 100. PACBIO: RECENT DEVELOPMENTS
TABLE 101. ILLUMINA INC. : FINANCIALS
TABLE 102. ILLUMINA INC. : PRODUCTS & SERVICES
TABLE 103. ILLUMINA INC. : DEVELOPMENTS
TABLE 104. AGILENT TECHNOLOGIES INC.: FINANCIALS
TABLE 105. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
TABLE 106. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
TABLE 107. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 108. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 109. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 110. OXFORD NANOPORE TECHNOLOGIES: FINANCIALS
TABLE 111. OXFORD NANOPORE TECHNOLOGIES: PRODUCTS & SERVICES
TABLE 112. OXFORD NANOPORE TECHNOLOGIES: RECENT DEVELOPMENTS

 

ページTOPに戻る


 

Summary

In the recent decade, the high cost of sequencing constituted a significant barrier to market expansion. The Human Genome Project needed USD 2.7 billion in funding in 2003 to sequence the first human genome. However, significant technical advancements in the field of genomics have occurred, with the goal of improving the speed and lowering the costs involved with sequencing.
For many years, the NHGRI (National Human Genome Research Institute, United States) has tracked sequencing prices at its many sponsored genome sequencing centres and calculated the cost of genome sequencing in the years following the Human Genome Project. Based on this data, the NHGRI estimated that in 2006, generating a finished human genome sequence would have cost more than USD 20-25 million, whereas by late 2015, the cost to generate a high-quality whole human genome sequence draft had fallen below USD 1,500, and the cost to generate a whole-exome sequence was generally less than USD 1,000.
Major firms in the gene expression sector are continually bringing new and improved technologies to the market. This enables the industry to see the introduction of more economical testing services. In January 2017, Illumina (US) unveiled the NovaSeq Series, which is predicted to reduce the cost of sequencing a genome/transcriptome to as little as USD 100 in the next years.
The lower cost of sequencing is likely to open up a slew of new prospects for healthcare players. For example, the low cost of sequencing would allow researchers to sequence the genomes of thousands of people, resulting in a better data set for determining the aetiology of diseases. Furthermore, the decreased cost would allow persons with uncommon disorders to be evaluated and treated more rapidly. As a result, the considerable decrease in sequencing costs is likely to be a major driver driving the growth of the gene expression analysis market.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Gene Expression Analysis Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Gene Expression Analysis Market , as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered. The primary participants share is given below:

The segmentation coverage of the study is provided below.
Gene Expression Analysis Market based on End User:
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Others
Gene Expression Analysis Market based on Product:
• Consumable
• Instruments
o Type
 Polymerase Chain Reaction
 Next Generation Sequencing
 DNA Microarrays
 Others
Gene Expression Analysis Market based on Application:
• Drug Discovery
• Diagnostics
Gene Expression Analysis Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
The gene expression market is divided into product, application, end-user, and geographical segments. The market is divided into two categories: consumables and instruments. Polymerase chain reaction, next generation sequencing, DNA microarrays, and other tools are subdivided further. It is divided into two categories based on application: drug discovery and diagnostics. Pharmaceutical and biotechnology businesses, academic and research organisations, and others are the end users. It is examined in North America, Europe, Asia-Pacific, and Latin America.
Next-Generation Sequencing (NGS) is a technique for determining the sequence of DNA or RNA in order to analyse genetic changes linked with illness. It is also known as massively parallel sequencing since it allows the sequencing to determine the sequencing of millions of DNA sequences at the same time.
Next-generation sequencing is predicted to rise significantly throughout the forecast period due to reasons such as an increase in the application of NGS technology in clinical diagnostics, as well as the speed, affordability, and accuracy of the sequencing process. Furthermore, the benefit of NGS over Sanger's sequencing approach, which gives accuracy results with modest sample input, is boosting market expansion.
The growing usage of next-generation sequencing technology in applications such as biomarker identification, cancer research, and personalised medicine is driving market expansion. For example, the rapid emergence of next-generation sequencing technology has revolutionised genomics and medical diagnosis, shifting from a gene-by-gene approach to a precision model based on syndrome-based panel sequencing, diagnostic exome sequencing (DES), and diagnostic genome sequencing (DGS). According to the Centres for Disease Control and Prevention, more than 60 million people globally will have their genomes sequenced by 2025, as nations take the initiative to analyse big populations. Furthermore, cell-free plasma next-generation sequencing (cfNGS) is used to diagnose viral, bacterial, and fungal infections in the blood by detecting pathogen DNA.
Furthermore, several initiatives launched by universities, academic and research organisations, and research institutes to employ next-generation sequencing technology to pinpoint the underlying cause of illnesses are expected to boost the segment's growth. For example, Roche will deploy the AVENIO Edge System in December 2021 to improve next-generation sequencing (NGS) technology. Cerba Research, meanwhile, introduced two COVID-19 exploratory tools, PCR-based and Next-Generation Sequencing-based, in January 2021, to increase research for vaccine development against infectious illnesses, including COVID-19. The next-generation sequencing-based assay considerably simplified whole-genome sequencing of respiratory viruses including SARS-CoV-2. Such advancements provide a significant boost to clinical research and organisations who are using next-generation sequencing as their foundation for innovation.
The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some market players are QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Novogene Corporation, PerkinElmer Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Promega Corporation, and Luminex Corporation. Regional and service portfolio expansions and mergers and acquisitions are key strategic undertakings adopted by these players.
• This report illustrates the most vital attributes of the Gene Expression Analysis Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Gene Expression Analysis Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Gene Expression Analysis Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Gene Expression Analysis Market.



ページTOPに戻る


Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. End User: Market Size & Analysis
5.1. Overview
5.2. Pharmaceutical and Biotechnology Companies
5.3. Academic and Research Institutes
5.4. Others
6. Product: Market Size & Analysis
6.1. Overview
6.2. Consumable
6.3. Instruments
7. Application: Market Size & Analysis
7.1. Overview
7.2. Drug Discovery
7.3. Diagnostics
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. QIAGEN
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F. Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. PerkinElmer Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Bio-Rad Laboratories, Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Promega Corporation
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. PACBIO
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Illumina Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Agilent Technologies Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Thermo Fisher Scientific Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Oxford Nanopore Technologies
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy

11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

ページTOPに戻る



List of Tables/Graphs

Tables
TABLE 1. GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 2. GENE EXPRESSION ANALYSIS MARKET VALUE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. GENE EXPRESSION ANALYSIS MARKET VALUE FOR ACADEMIC AND RESEARCH INSTITUTES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. GENE EXPRESSION ANALYSIS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 6. GENE EXPRESSION ANALYSIS MARKET VALUE FOR CONSUMABLE, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. GENE EXPRESSION ANALYSIS MARKET VALUE FOR INSTRUMENTS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 9. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DRUG DISCOVERY , BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. GENE EXPRESSION ANALYSIS MARKET VALUE FOR DIAGNOSTICS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 15. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 16. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 17. U.S GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 19. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 20. CANADA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 21. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 22. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 23. MEXICO GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 24. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 25. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 26. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 27. EUROPE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 28. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 29. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 30. GERMANY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 32. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 33. U.K GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 34. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 35. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. FRANCE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 37. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 38. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 39. ITALY GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 40. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 41. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 42. SPAIN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 43. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 44. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 45. ROE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 46. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 47. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 48. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. ASIA PACIFIC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 51. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 52. CHINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 53. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 54. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 55. INDIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 57. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 58. JAPAN GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 59. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 60. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 61. REST OF APAC GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 62. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 63. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 64. LATIN AMERICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 65. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 66. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 67. BRAZIL GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 68. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 69. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 70. ARGENTINA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 71. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 72. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 73. MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 74. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 75. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 76. SAUDI ARABIA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 77. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 78. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 79. UAE GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 80. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 81. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 82. REST OF MIDDLE EAST AND AFRICA GENE EXPRESSION ANALYSIS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 83. QIAGEN : FINANCIALS
TABLE 84. QIAGEN : PRODUCTS & SERVICES
TABLE 85. QIAGEN : RECENT DEVELOPMENTS
TABLE 86. F. HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 87. F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 88. F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 89. PERKINELMER INC.: FINANCIALS
TABLE 90. PERKINELMER INC.: PRODUCTS & SERVICES
TABLE 91. PERKINELMER INC.: RECENT DEVELOPMENTS
TABLE 92. BIO-RAD LABORATORIES, INC.: FINANCIALS
TABLE 93. BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES
TABLE 94. BIO-RAD LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 95. PROMEGA CORPORATION: FINANCIALS
TABLE 96. PROMEGA CORPORATION: PRODUCTS & SERVICES
TABLE 97. PROMEGA CORPORATION: RECENT DEVELOPMENTS
TABLE 98. PACBIO: FINANCIALS
TABLE 99. PACBIO: PRODUCTS & SERVICES
TABLE 100. PACBIO: RECENT DEVELOPMENTS
TABLE 101. ILLUMINA INC. : FINANCIALS
TABLE 102. ILLUMINA INC. : PRODUCTS & SERVICES
TABLE 103. ILLUMINA INC. : DEVELOPMENTS
TABLE 104. AGILENT TECHNOLOGIES INC.: FINANCIALS
TABLE 105. AGILENT TECHNOLOGIES INC.: PRODUCTS & SERVICES
TABLE 106. AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS
TABLE 107. THERMO FISHER SCIENTIFIC INC.: FINANCIALS
TABLE 108. THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES
TABLE 109. THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS
TABLE 110. OXFORD NANOPORE TECHNOLOGIES: FINANCIALS
TABLE 111. OXFORD NANOPORE TECHNOLOGIES: PRODUCTS & SERVICES
TABLE 112. OXFORD NANOPORE TECHNOLOGIES: RECENT DEVELOPMENTS

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

IHR Insights社の医療分野での最新刊レポート

本レポートと同じKEY WORD(analysis market)の最新刊レポート


よくあるご質問


IHR Insights社はどのような調査会社ですか?


IHR InsightsはICT、化学品、ヘルスケア、半導体など、世界の幅広い分野を対象に調査し、専門的な知識を基に市場調査報告書を出版しています。 主な調査分野 ◇ICT ◇化学品、材料、... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る